As a result of the firm's financial results, Castle Bio raised its full-year 2025 revenue guidance to between $327 and $335 million from a range of $310 to $320 million.

Of the 30 companies in the index, 21 firms saw their share prices rise month over month, while nine saw their stock prices decline.

Last week, readers were most interested in a story about Biodesix's journey as a publicly traded company and what lies ahead for it.

The Dublin-based firm is developing an array of artificial intelligence-derived tools to improve the efficiency of its digital pathology outsourcing service.

The blood-based test detects phosphorylated tau 181, a biomarker that is correlated with the presence of amyloid pathology in ...

Medicare Part B data show that of the 20 CPT codes seeing the largest increase in payments from 2022 to 2024, all are for molecular- or sequencing-based tests.

Called the RESULTS Act, the bill would use a third-party database to set Medicare payment rates and would delay price cuts and data reporting scheduled for 2026.

NEW YORK – Qiagen announced Thursday that the US Food and Drug Administration has granted it expanded clearance for the use of Copan FecalSwab sample collection for gastrointestinal panels on its ...

NEW YORK — Tosoh Bioscience said on Thursday that it has received 510 (k) clearance from the US Food and Drug Administration for its automated HLC-723 GR01 glycohemoglobin A1c (HbA1c) analyzer.

Biodesix officials at Nasdaq earlier this week. From left to right are Chief Development Officer Gary Pestano, CEO Scott Hutton, CFO Robin Harper Cowie, and COO Kieran O'Kane. Credit: Biodesix NEW ...

The Simplexa COVID-19/Flu A/B  & RSV Direct Kit is used for the detection and differentiation of infections with SARS-CoV-2, flu A/B, and respiratory syncytial viruses.

The Netherlands-based company will develop a low-cost, rapid point-of-care test using its Visualization by Infrared PEptide Reaction (VIPER) technology.